Bullous pemphigoid induced by nivolumab in a patient with malignant melanoma

Eriko Adachi, Erina Yokoyama, Yuna Yamagami, Reiko Koga, Yoshiaki Yoshikawa

Article ID: 1210
Vol 4, Issue 1, 2020

VIEWS - 689 (Abstract)

Abstract


Immune checkpoint inhibitors, such as nivolumab, have been recognized that the enhanced immune responses often lead to immune-related adverse events (irAEs) in various organs. Although cutaneous toxicity is one of the most common irAEs, bullous pemphigoid (BP) with immune checkpoint inhibitors is rare. Herein, the authors report a case of BP in a patient of the metastatic malignant melanoma of the brain under the treatment of nivolumab. It is notable that this case showed the clear correlation between the status of using of nivolumab and serum levels of anti-BP180 antibody. In addition, the skin eruptions in the case were mainly pruritic erosive or crusted papules and these clinical features may be the clinical characteristics of BP induced by nivolumab.


Keywords


Immune-related Adverse Events (irAEs); Immune Checkpoint Inhibitors; Nivolumab; Bullous Pemphigoid (BP); Malignant Melanoma

Full Text:

PDF


References


1. Seidal JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors. Rationale and limitations. Trend Immunother 2017; 1(1): 2-9. doi: 10.24294/ti.v1.i1.20.

2. Furukawa F. The Nobel Prize in Physiology or Medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trend Immunother 2018; 2(3). doi: 10.24294/ti.v2.i3.1065.

3. Grimaux X, Delva R, Jadaud E, et al. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas J Dermatol. 2019; 60: e235-e236. doi: 10.1111/ajd.12987.

4. Panariello L, Fattore D, Annunziata MC, et al. Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy. Eur J Cancer. 2018; 103: 284-286. doi: 10.1016/j.ejca.2018.08.022.

5. Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist. 2018; 23(10): 1119-1126. doi: 10.1634/theoncologist.2018-0128.

6. Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018; 57(6): 664-669. doi: 10.1111/ijd.13984.

7. Ridpath AV, Rzepka PV, Shearer SM, et al. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol. 2018; 57(11): 1372-4. doi: 10.1111/ijd.13970.




DOI: https://doi.org/10.24294/ti.v4.i1.1210

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Eriko Adachi, Erina Yokoyama, Yuna Yamagami, Reiko Koga, Yoshiaki Yoshikawa

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.